|
The Mo.Ma Trial “Proximal Endovascular Flow Blockage for Cerebral Protection During Carotid Artery Stenting: Results from a Prospective European Multicenter Registry”*:
• 157 patients (75.2% high surgical risk).
• 100% procedural success.
• 7.6% intolerance to flow blockage.
• 79% macroscopic evidence of debris.
• All Stroke and Death 2.5% In Hospital and 3.2% @ 30 days.
*Reimers B. et al., JEndovasc Ther. 2005; 12: 156-165
The Priamus Registry “Proximal Endovascular Flow Blockage for Cerebral Protection During Carotid Artery Stenting: Results from a Multicenter Italian Registry”*:
• 416 patients (63.5% symptomatic, 50.7% heterogeneous soft lesions).
• 99.03% technical success (ability to position and establish protection with the MO.MA and deploy the stent).
• 5.7% intolerance to flow blockage.
• 58.9% macroscopic evidence of debris after filtering the blood.
• 4.91 min. ± 1.1 mean flow blockage time.
• All Stroke and Death 4.56% In-Hospital and 0% @ 30 days.
*Coppi, G. et al., JCardiovasc Surg 2005; 46: 219-27
Treatment of soft carotid lesions “Endovascular Treatment of Soft Carotid Plaques:
a single-center carotid stent experience”*:
• 84 patients (100% soft echolucent carotid lesions, 84.1%±8.4% stenosis rate).
• 100% technical success (ability to position and establish protection with the MoMa and deploy the stent).
• 5.9% intolerance of flow blockage.
• 66.7 % macroscopic evidence of debris after filtering the blood.
• 4.8% neurological events at 30-day (3 TIAs and 1 minor stroke).
• All Stroke and Death 2.4%. |
